{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T01:24:38Z","timestamp":1782523478028,"version":"3.54.5"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts Universitaris i de Recerca","doi-asserted-by":"crossref","award":["2021SGR00002"],"award-info":[{"award-number":["2021SGR00002"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts Universitaris i de Recerca","doi-asserted-by":"crossref","award":["2021SGR00782"],"award-info":[{"award-number":["2021SGR00782"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["CPP2021-008475"],"award-info":[{"award-number":["CPP2021-008475"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministerio Ciencia e Innovaci\u00f3n y Universidades","award":["CPP2021-008475"],"award-info":[{"award-number":["CPP2021-008475"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"DOI":"10.1186\/s12974-025-03618-w","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:57:46Z","timestamp":1764331066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reprogramming autoimmunity: inducing antigen-specific tolerance via apoptotic mimicry in an experimental model of multiple sclerosis"],"prefix":"10.1186","volume":"22","author":[{"given":"Herena","family":"Eixarch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"Boutitah-Benyaich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Plaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00edlvia","family":"Rodr\u00edguez-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00edriam","family":"Salvad\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Mancera-Arteu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Almenara-Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00ed","family":"Dalmases","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Vives-Pi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Barneda-Zahonero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Espejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"3618_CR1","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1177\/1352458520968811","volume":"26","author":"T Coetzee","year":"2020","unstructured":"Coetzee T, Thompson AJ. Atlas of MS 2020: informing global policy change. Mult Scler. 2020;26:1807\u20138.","journal-title":"Mult Scler"},{"key":"3618_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature10251","volume":"476","author":"C Sawcer","year":"2011","unstructured":"Genetics IMS, Wellcome Trust Case Control C, Sawcer C, Hellenthal S, Pirinen G, Spencer M, Patsopoulos CC, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476:214\u20139.","journal-title":"Nature"},{"key":"3618_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","volume":"13","author":"T Olsson","year":"2017","unstructured":"Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13:25\u201336.","journal-title":"Nat Rev Neurol"},{"key":"3618_CR4","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028944","author":"L Alfredsson","year":"2019","unstructured":"Alfredsson L, Olsson T. Lifestyle and environmental factors in multiple sclerosis. Cold Spring Harb Perspect Med. 2019. https:\/\/doi.org\/10.1101\/cshperspect.a028944.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3618_CR5","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.cell.2020.09.054","volume":"183","author":"J Wang","year":"2020","unstructured":"Wang J, Jelcic I, Muhlenbruch L, Haunerdinger V, Toussaint NC, Zhao Y, Cruciani C, Faigle W, Naghavian R, Foege M, et al. HLA-DR15 molecules jointly shape an autoreactive T cell repertoire in multiple sclerosis. Cell. 2020;183:1264\u2013e12811220.","journal-title":"Cell"},{"key":"3618_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/0167-5699(93)90244-F","volume":"14","author":"NR Rose","year":"1993","unstructured":"Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky\u2019s postulates revisited). Immunol Today. 1993;14:426\u201330.","journal-title":"Immunol Today"},{"key":"3618_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/s-0036-1579739","volume":"36","author":"M Sospedra","year":"2016","unstructured":"Sospedra M, Martin R. Immunology of multiple sclerosis. Semin Neurol. 2016;36:115\u201327.","journal-title":"Semin Neurol"},{"key":"3618_CR8","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nri2190","volume":"7","author":"AG Baxter","year":"2007","unstructured":"Baxter AG. The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol. 2007;7:904\u201312.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"3618_CR9","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1474-4422(14)70305-9","volume":"14","author":"B Hemmer","year":"2015","unstructured":"Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 2015;14(4):406\u201319.","journal-title":"Lancet Neurol"},{"key":"3618_CR10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2221544120","volume":"120","author":"M Heming","year":"2023","unstructured":"Heming M, Wiendl H. Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy. Proc Natl Acad Sci USA. 2023;120:e2221544120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3618_CR11","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676\u201388.","journal-title":"N Engl J Med"},{"key":"3618_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221\u201334.","journal-title":"N Engl J Med"},{"key":"3618_CR13","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383:546\u201357.","journal-title":"N Engl J Med"},{"key":"3618_CR14","doi-asserted-by":"publisher","first-page":"175628642110396","DOI":"10.1177\/17562864211039648","volume":"14","author":"H Wiendl","year":"2021","unstructured":"Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Maurer M, Aktas O, Baum K, Berghoff M, Bittner S, et al. Multiple sclerosis therapy consensus group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord. 2021;14:17562864211039648.","journal-title":"Ther Adv Neurol Disord"},{"key":"3618_CR15","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/joim.13215","volume":"289","author":"F Piehl","year":"2021","unstructured":"Piehl F. Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis. J Intern Med. 2021;289:771\u201391.","journal-title":"J Intern Med"},{"key":"3618_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103312","volume":"22","author":"FF Konen","year":"2023","unstructured":"Konen FF, Mohn N, Witte T, Schefzyk M, Wiestler M, Lovric S, et al. Treatment of autoimmunity: the impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. Autoimmun Rev. 2023;22:103312.","journal-title":"Autoimmun Rev"},{"key":"3618_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/1352458520949158","volume":"28","author":"AL Jordan","year":"2022","unstructured":"Jordan AL, Yang J, Fisher CJ, Racke MK, Mao-Draayer Y. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. Mult Scler. 2022;28:7\u201315.","journal-title":"Mult Scler"},{"key":"3618_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, et al. A placebo-controlled trial of oral Fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387\u2013401.","journal-title":"N Engl J Med"},{"key":"3618_CR19","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/S0140-6736(12)62190-4","volume":"381","author":"R Gold","year":"2013","unstructured":"Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:2167\u201375.","journal-title":"Lancet"},{"key":"3618_CR20","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899\u2013910.","journal-title":"N Engl J Med"},{"key":"3618_CR21","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","volume":"365","author":"P O\u2019Connor","year":"2011","unstructured":"O\u2019Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, et al. Randomized trial of oral Teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293\u2013303.","journal-title":"N Engl J Med"},{"key":"3618_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.640935","volume":"12","author":"A Lutterotti","year":"2021","unstructured":"Lutterotti A, Hayward-Koennecke H, Sospedra M, Martin R. Antigen-specific immune tolerance in multiple sclerosis-promising approaches and how to bring them to patients. Front Immunol. 2021;12:640935.","journal-title":"Front Immunol"},{"key":"3618_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00472","volume":"11","author":"JM Carballido","year":"2020","unstructured":"Carballido JM, Regairaz C, Rauld C, Raad L, Picard D, Kammuller M. The emerging jamboree of transformative therapies for autoimmune diseases. Front Immunol. 2020;11:472.","journal-title":"Front Immunol"},{"key":"3618_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.624685","volume":"12","author":"J Derdelinckx","year":"2021","unstructured":"Derdelinckx J, Cras P, Berneman ZN, Cools N. Antigen-specific treatment modalities in MS: the past, the present, and the future. Front Immunol. 2021;12:624685.","journal-title":"Front Immunol"},{"key":"3618_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nri3607","volume":"14","author":"IK Poon","year":"2014","unstructured":"Poon IK, Lucas CD, Rossi AG, Ravichandran KS. Apoptotic cell clearance: basic biology and therapeutic potential. Nat Rev Immunol. 2014;14:166\u201380.","journal-title":"Nat Rev Immunol"},{"key":"3618_CR26","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.4049\/jimmunol.148.7.2207","volume":"148","author":"VA Fadok","year":"1992","unstructured":"Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol. 1992;148:2207\u201316.","journal-title":"J Immunol"},{"key":"3618_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0003-9861(03)00083-3","volume":"413","author":"GG Borisenko","year":"2003","unstructured":"Borisenko GG, Matsura T, Liu SX, Tyurin VA, Jianfei J, Serinkan FB, et al. Macrophage recognition of externalized phosphatidylserine and phagocytosis of apoptotic Jurkat cells\u2013existence of a threshold. Arch Biochem Biophys. 2003;413:41\u201352.","journal-title":"Arch Biochem Biophys"},{"key":"3618_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10495-015-1090-8","volume":"20","author":"M Vives-Pi","year":"2015","unstructured":"Vives-Pi M, Rodriguez-Fernandez S, Pujol-Autonell I. How apoptotic beta-cells direct immune response to tolerance or to autoimmune diabetes: a review. Apoptosis. 2015;20:263\u201372.","journal-title":"Apoptosis"},{"key":"3618_CR29","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2217\/nnm-2016-0410","volume":"12","author":"I Pujol-Autonell","year":"2017","unstructured":"Pujol-Autonell I, Mansilla MJ, Rodriguez-Fernandez S, Cano-Sarabia M, Navarro-Barriuso J, Ampudia RM, et al. Liposome-based immunotherapy against autoimmune diseases: therapeutic effect on multiple sclerosis. Nanomedicine. 2017;12:1231\u201342.","journal-title":"Nanomedicine"},{"key":"3618_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127057","volume":"10","author":"I Pujol-Autonell","year":"2015","unstructured":"Pujol-Autonell I, Serracant-Prat A, Cano-Sarabia M, Ampudia RM, Rodriguez-Fernandez S, Sanchez A, et al. Use of autoantigen-loaded phosphatidylserine-liposomes to arrest autoimmunity in type 1 diabetes. PLoS One. 2015;10:e0127057.","journal-title":"PLoS One"},{"key":"3618_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2022.102635","volume":"48","author":"L Almenara-Fuentes","year":"2023","unstructured":"Almenara-Fuentes L, Rodriguez-Fernandez S, Rosell-Mases E, Kachler K, You A, Salvado M, et al. A new platform for autoimmune diseases. Inducing tolerance with liposomes encapsulating autoantigens. Nanomedicine. 2023;48:102635.","journal-title":"Nanomedicine"},{"key":"3618_CR32","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1007\/s12035-016-0154-2","volume":"54","author":"A Gutierrez-Franco","year":"2017","unstructured":"Gutierrez-Franco A, Eixarch H, Costa C, Gil V, Castillo M, Calvo-Barreiro L, et al. Semaphorin 7A as a potential therapeutic target for multiple sclerosis. Mol Neurobiol. 2017;54:4820\u201331.","journal-title":"Mol Neurobiol"},{"key":"3618_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jneuroim.2011.11.003","volume":"242","author":"D Baker","year":"2012","unstructured":"Baker D, Amor S. Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2012;242:78\u201383.","journal-title":"J Neuroimmunol"},{"key":"3618_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103196","volume":"145","author":"I Garcia-Loza","year":"2024","unstructured":"Garcia-Loza I, Perna-Barrull D, Aguilera E, Almenara-Fuentes L, Gomez-Munoz L, Greco D, et al. Targeting macrophages with phosphatidylserine-rich liposomes as a potential antigen-specific immunotherapy for type 1 diabetes. J Autoimmun. 2024;145:103196.","journal-title":"J Autoimmun"},{"key":"3618_CR35","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/nature16962","volume":"530","author":"X Clemente-Casares","year":"2016","unstructured":"Clemente-Casares X, Blanco J, Ambalavanan P, Yamanouchi J, Singha S, Fandos C, et al. Expanding antigen-specific regulatory networks to treat autoimmunity. Nature. 2016;530:434\u201340.","journal-title":"Nature"},{"key":"3618_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02811","volume":"10","author":"S Rodriguez-Fernandez","year":"2019","unstructured":"Rodriguez-Fernandez S, Murillo M, Villalba A, Perna-Barrull D, Cano-Sarabia M, Gomez-Munoz L, et al. Impaired phagocytosis in dendritic cells from pediatric patients with type 1 diabetes does not hamper their tolerogenic potential. Front Immunol. 2019;10:2811.","journal-title":"Front Immunol"},{"key":"3618_CR37","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1182\/blood-2006-12-064527","volume":"110","author":"G Borsellino","year":"2007","unstructured":"Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Hopner S, Centonze D, Bernardi G, Dell\u2019Acqua ML, et al. Expression of ectonucleotidase CD39 by Foxp3\u2009+\u2009Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110:1225\u201332.","journal-title":"Blood"},{"key":"3618_CR38","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.4049\/jimmunol.1001307","volume":"185","author":"T Matsushita","year":"2010","unstructured":"Matsushita T, Horikawa M, Iwata Y, Tedder TF. Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol. 2010;185:2240\u201352.","journal-title":"J Immunol"},{"key":"3618_CR39","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/ni1391","volume":"7","author":"M Veldhoen","year":"2006","unstructured":"Veldhoen M, Hocking RJ, Flavell RA, Stockinger B. Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat Immunol. 2006;7:1151\u20136.","journal-title":"Nat Immunol"},{"key":"3618_CR40","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1006\/cimm.1998.1365","volume":"188","author":"EB Samoilova","year":"1998","unstructured":"Samoilova EB, Horton JL, Chen Y. Acceleration of experimental autoimmune encephalomyelitis in interleukin-10-deficient mice: roles of interleukin-10 in disease progression and recovery. Cell Immunol. 1998;188:118\u201324.","journal-title":"Cell Immunol"},{"key":"3618_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00253","volume":"9","author":"S Rodriguez-Fernandez","year":"2018","unstructured":"Rodriguez-Fernandez S, Pujol-Autonell I, Brianso F, Perna-Barrull D, Cano-Sarabia M, Garcia-Jimeno S, et al. Phosphatidylserine-liposomes promote tolerogenic features on dendritic cells in human type 1 diabetes by apoptotic mimicry. Front Immunol. 2018;9:253.","journal-title":"Front Immunol"},{"key":"3618_CR42","doi-asserted-by":"crossref","unstructured":"Morton DB, Jennings M, Buckwell A, Ewbank R, Godfrey C, Holgate B, Inglis I, James R, Page C, Sharman I, BVAAWF\/FRAME\/RSPCA\/UFAW Joint Working Group on Refinement. Refining procedures for the administration of substances. Report of the. British Veterinary Association Animal Welfare Foundation\/Fund for the Replacement of Animals in Medical Experiments\/Royal Society for the Prevention of Cruelty to Animals\/Universities Federation for Animal Welfare. Lab Anim. 2001;35:1\u201341.","DOI":"10.1258\/0023677011911345"},{"key":"3618_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107177","volume":"90","author":"A Tajbakhsh","year":"2021","unstructured":"Tajbakhsh A, Farahani N, Gheibihayat SM, Mirkhabbaz AM, Savardashtaki A, Hamblin MR, et al. Autoantigen-specific immune tolerance in pathological and physiological cell death: nanotechnology comes into view. Int Immunopharmacol. 2021;90:107177.","journal-title":"Int Immunopharmacol"},{"key":"3618_CR44","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1365-2249.2009.04082.x","volume":"160","author":"S Marin-Gallen","year":"2010","unstructured":"Marin-Gallen S, Clemente-Casares X, Planas R, Pujol-Autonell I, Carrascal J, Carrillo J, et al. Dendritic cells pulsed with antigen-specific apoptotic bodies prevent experimental type 1 diabetes. Clin Exp Immunol. 2010;160:207\u201314.","journal-title":"Clin Exp Immunol"},{"key":"3618_CR45","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/mt.2009.42","volume":"17","author":"H Eixarch","year":"2009","unstructured":"Eixarch H, Espejo C, Gomez A, Mansilla MJ, Castillo M, Mildner A, et al. Tolerance induction in experimental autoimmune encephalomyelitis using non-myeloablative hematopoietic gene therapy with autoantigen. Mol Ther. 2009;17:897\u2013905.","journal-title":"Mol Ther"},{"key":"3618_CR46","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.expneurol.2016.09.012","volume":"286","author":"S Casacuberta-Serra","year":"2016","unstructured":"Casacuberta-Serra S, Costa C, Eixarch H, Mansilla MJ, Lopez-Estevez S, Martorell L, et al. Myeloid-derived suppressor cells expressing a self-antigen ameliorate experimental autoimmune encephalomyelitis. Exp Neurol. 2016;286:50\u201360.","journal-title":"Exp Neurol"},{"key":"3618_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba0599","author":"G Casella","year":"2020","unstructured":"Casella G, Rasouli J, Boehm A, Zhang W, Xiao D, Ishikawa LLW, et al. Oligodendrocyte-derived extracellular vesicles as antigen-specific therapy for autoimmune neuroinflammation in mice. Sci Transl Med. 2020. https:\/\/doi.org\/10.1126\/scitranslmed.aba0599.","journal-title":"Sci Transl Med"},{"key":"3618_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1029356","volume":"13","author":"Y Cai","year":"2022","unstructured":"Cai Y, Schroeder JA, Jing W, Gurski C, Williams CB, Wang S, et al. Targeting transmembrane-domain-less MOG expression to platelets prevents disease development in experimental autoimmune encephalomyelitis. Front Immunol. 2022;13:1029356.","journal-title":"Front Immunol"},{"key":"3618_CR49","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1001\/archneur.64.10.nct70002","volume":"64","author":"A Bar-Or","year":"2007","unstructured":"Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1\/2 trial. Arch Neurol. 2007;64:1407\u201315.","journal-title":"Arch Neurol"},{"key":"3618_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-030309","volume":"9","author":"B Willekens","year":"2019","unstructured":"Willekens B, Presas-Rodriguez S, Mansilla MJ, Derdelinckx J, Lee WP, Nijs G, et al. Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration. BMJ Open. 2019;9:e030309.","journal-title":"BMJ Open"},{"key":"3618_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006168","volume":"5","author":"A Lutterotti","year":"2013","unstructured":"Lutterotti A, Yousef S, Sputtek A, Sturner KH, Stellmann JP, Breiden P, et al. Antigen-specific tolerance by autologous myelin peptide\u2013coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med. 2013;5:188ra175.","journal-title":"Sci Transl Med"},{"key":"3618_CR52","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/imm.13320","volume":"163","author":"AA Patel","year":"2021","unstructured":"Patel AA, Ginhoux F, Yona S. Monocytes, macrophages, dendritic cells and neutrophils: an update on lifespan kinetics in health and disease. Immunology. 2021;163:250\u201361.","journal-title":"Immunology"},{"key":"3618_CR53","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.it.2022.12.006","volume":"44","author":"J Bourque","year":"2023","unstructured":"Bourque J, Hawiger D. Life and death of tolerogenic dendritic cells. Trends Immunol. 2023;44:110\u20138.","journal-title":"Trends Immunol"},{"key":"3618_CR54","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/ni1462","volume":"8","author":"K Liu","year":"2007","unstructured":"Liu K, Waskow C, Liu X, Yao K, Hoh J, Nussenzweig M. Origin of dendritic cells in peripheral lymphoid organs of mice. Nat Immunol. 2007;8:578\u201383.","journal-title":"Nat Immunol"},{"key":"3618_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110657","volume":"39","author":"CA Iberg","year":"2022","unstructured":"Iberg CA, Bourque J, Fallahee I, Son S, Hawiger D. TNF-alpha sculpts a maturation process in vivo by pruning tolerogenic dendritic cells. Cell Rep. 2022;39:110657.","journal-title":"Cell Rep"},{"key":"3618_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-018-0017-6","volume":"24","author":"I Tabansky","year":"2018","unstructured":"Tabansky I, Keskin DB, Watts D, Petzold C, Funaro M, Sands W, et al. Targeting DEC-205(-)DCIR2(+) dendritic cells promotes immunological tolerance in proteolipid protein-induced experimental autoimmune encephalomyelitis. Mol Med. 2018;24:17.","journal-title":"Mol Med"},{"key":"3618_CR57","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jaut.2016.05.007","volume":"72","author":"DK Challa","year":"2016","unstructured":"Challa DK, Mi W, Lo ST, Ober RJ, Ward ES. Antigen dynamics govern the induction of CD4(+) T cell tolerance during autoimmunity. J Autoimmun. 2016;72:84\u201394.","journal-title":"J Autoimmun"},{"key":"3618_CR58","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.4049\/jimmunol.172.6.3893","volume":"172","author":"B Bielekova","year":"2004","unstructured":"Bielekova B, Sung MH, Kadom N, Simon R, McFarland H, Martin R. Expansion and functional relevance of high-avidity myelin-specific CD4\u2009+\u2009T cells in multiple sclerosis. J Immunol. 2004;172:3893\u2013904.","journal-title":"J Immunol"},{"key":"3618_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/anbr.202200135","author":"MA Ackun-Farmmer","year":"2023","unstructured":"Ackun-Farmmer MA, Jewell CM. Delivery route considerations for designing antigen-specific biomaterial strategies to combat autoimmunity. Adv NanoBiomed Res. 2023. https:\/\/doi.org\/10.1002\/anbr.202200135.","journal-title":"Adv NanoBiomed Res"},{"key":"3618_CR60","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.4049\/jimmunol.1004175","volume":"187","author":"DR Getts","year":"2011","unstructured":"Getts DR, Turley DM, Smith CE, Harp CT, McCarthy D, Feeney EM, et al. Tolerance Induced by Apoptotic Antigen-Coupled Leukocytes Is Induced by PD-L1+ and IL-10\u2013Producing Splenic Macrophages and Maintained by T Regulatory Cells. J Immunol. 2011;187:2405\u201317.","journal-title":"J Immunol"},{"key":"3618_CR61","doi-asserted-by":"publisher","first-page":"11270","DOI":"10.1073\/pnas.1120611109","volume":"109","author":"A Yeste","year":"2012","unstructured":"Yeste A, Nadeau M, Burns EJ, Weiner HL, Quintana FJ. Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2012;109:11270\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3618_CR62","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1073\/pnas.1109173109","volume":"109","author":"K Miles","year":"2012","unstructured":"Miles K, Heaney J, Sibinska Z, Salter D, Savill J, Gray D, et al. A tolerogenic role for Toll-like receptor 9 is revealed by B-cell interaction with DNA complexes expressed on apoptotic cells. Proc Natl Acad Sci USA. 2012;109:887\u201392.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3618_CR63","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1016\/j.ajpath.2012.03.010","volume":"180","author":"M Yang","year":"2012","unstructured":"Yang M, Deng J, Liu Y, Ko KH, Wang X, Jiao Z, et al. IL-10\u2013producing regulatory B10 cells ameliorate collagen-induced arthritis via suppressing Th17 cell generation. Am J Pathol. 2012;180:2375\u201385.","journal-title":"Am J Pathol"},{"key":"3618_CR64","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12929-017-0391-3","volume":"24","author":"CH Chien","year":"2017","unstructured":"Chien CH, Chiang BL. Regulatory T cells induced by B cells: a novel subpopulation of regulatory T cells. J Biomed Sci. 2017;24:86.","journal-title":"J Biomed Sci"},{"key":"3618_CR65","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/ana.22081","volume":"68","author":"MS Weber","year":"2010","unstructured":"Weber MS, Prod\u2019homme T, Patarroyo JC, Molnarfi N, Karnezis T, Lehmann-Horn K, Danilenko DM, Eastham-Anderson J, Slavin AJ, Linington C, et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol. 2010;68:369\u201383.","journal-title":"Ann Neurol"},{"key":"3618_CR66","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.4049\/jimmunol.1103354","volume":"188","author":"A Ray","year":"2012","unstructured":"Ray A, Basu S, Williams CB, Salzman NH, Dittel BN. A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. J Immunol. 2012;188:3188\u201398.","journal-title":"J Immunol"},{"key":"3618_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-146","volume":"8","author":"K Lehmann-Horn","year":"2011","unstructured":"Lehmann-Horn K, Schleich E, Hertzenberg D, Hapfelmeier A, Kumpfel T, von Bubnoff N, et al. Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. J Neuroinflammation. 2011;8:146.","journal-title":"J Neuroinflammation"},{"key":"3618_CR68","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.4049\/jimmunol.179.4.2046","volume":"179","author":"X Chen","year":"2007","unstructured":"Chen X, Jensen PE. Cutting edge: primary B lymphocytes preferentially expand allogeneic FoxP3\u2009+\u2009CD4 T cells. J Immunol. 2007;179:2046\u201350.","journal-title":"J Immunol"},{"key":"3618_CR69","doi-asserted-by":"publisher","first-page":"14080","DOI":"10.1073\/pnas.0700326104","volume":"104","author":"M Gray","year":"2007","unstructured":"Gray M, Miles K, Salter D, Gray D, Savill J. Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells. Proc Natl Acad Sci U S A. 2007;104:14080\u20135.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03618-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-025-03618-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03618-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T14:19:27Z","timestamp":1764339567000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-025-03618-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3618"],"URL":"https:\/\/doi.org\/10.1186\/s12974-025-03618-w","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"All experiments were performed in strict accordance with EU (Directive 2010\/63\/UE) and Spanish regulations (Real Decreto 53\/2013; Generalitat de Catalunya Decret 214\/97). The Ethics Committee on Animal Experimentation of the Vall d\u2019Hebron Research Institute approved all procedures described in this study (protocol ID CEEA 26\/18: CEA-OH\/10092\/2; CEEA 09\/19: CEA-OH\/11203\/2; CEEA 17\/19: CEA-OH\/106684\/3; CEEA 46\/19: CEA-OH\/9459R1\/2).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MVP is co-founder and CSO of Ahead Therapeutics SL. BBZ, SRV, MS, JP and MD are employees of AHEAD Therapeutics SL. CE, BBZ, MVP, SRV, MD and HE hold a patent that relate to liposome immunotherapy for autoimmune diseases, licensed to Ahead Therapeuthics SL. This work was funded by Ahead Therapeutics SL. XM\u2019s institution has received compensation for lecture honoraria and travel expenses, participation in scientific meetings, clinical trial steering committee membership, or clinical advisory board participation in recent years from Abbvie, Actelion, Alexion, Bial PD, Biogen, Bristol-Myers Squibb\/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic Therapeutics, Janssen Pharmaceuticals, Medday, Medscape, Merck, Mylan, Nervgen, Neuraxpharm, Novartis, Peervoice, Samsung-Biosys, Sandoz, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, ECTRIMS, MSIF, and NMSS or any of their affiliates.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"281"}}